Find the right test Across the Cancer Journey.
Explore clinically validated genomic tests organized by stage, use case, and clinical objective.
- OncoTarget®
- OncoHRD®
- OncoIndx 360® Endometrium
- OncoPredikt® BRS
- OncoIndx® Multi-Modal
- OncoIndx® Prime+
- OncoMonitor® MRD
- OncoAlibrex®
- OncoRisk®
- IHC Biomarkers
- DrG Application
Early-stage Treatment Selection
Guide the first treatment decision.
Comprehensive molecular profiling reveals actionable biomarkers to support confident first-line therapy selection from the time of diagnosis.
108-gene targeted panel for rapid, actionable first-line profiling —
tissue or liquid.
Ideal for
Comprehensive homologous recombination deficiency scoring for BRCA-mutated and BRCA-wild-type patients alike.
Ideal for
WHO-aligned molecular classification integrating POLE, TP53, MMR, MSI and IHC in a single guideline-ready report.
Ideal for
India's first AI-powered breast cancer recurrence score — guides the treat-or-watch adjuvant chemo decision.
Ideal for
Advanced Precision Oncology
Navigate complex treatment decisions.
Advanced genomic insights identify new therapeutic opportunities, resistance mechanisms, and clinical trial options when standard treatments are no longer sufficient.
Integrated DNA, RNA, and protein profiling with AI-powered interpretation for a complete view of tumor biology.
Ideal for
Five integrated biological layers combining DNA, RNA, protein, ctDNA, & normal-match analysis for the most comprehensive tumour profiling.
Ideal for
Monitoring & Response
Track treatment with confidence.
Longitudinal molecular monitoring helps assess treatment effectiveness, detect disease progression, and support timely adjustments throughout patient care.
Ultra-sensitive ctDNA and methylation testing for minimal residual disease, with integrated 12-month clinical monitoring and Concierge support.
Ideal for
Fragmentomics-based blood test that predicts treatment response within weeks, helping clinicians evaluate therapy before imaging changes appear.
Ideal for
Complementary Solutions
Expand clinical insights.
Specialized diagnostic solutions provide additional molecular evidence for hereditary risk assessment, companion diagnostics, and disease-specific clinical decision support.
74 NCCN-recommended genes plus 28 MLPA probes covering SNVs
& CNVs across 11+ hereditary cancer syndromes.
Ideal for
Comprehensive IHC biomarker analysis to support accurate diagnosis and precision treatment decisions.
Ideal for
An AI-powered clinical workspace that brings patient records, molecular reports, and decision support together in one seamless experience.
Ideal for
Reports That Drive Clinical Decisions
Every 1Cell.AI report transforms complex genomic data into clear, evidence-backed clinical guidance—helping oncologists identify actionable therapies, interpret negative findings with confidence, and make faster treatment decisions.
- Featured Capability
From Data to Clinical Action
Our reports prioritize the findings that matter most, giving clinicians clear therapeutic direction without searching through pages of genomic data.
- Therapy Ready
Actionable Findings First
Clinically significant variants are prioritized with matched targeted therapies, ensuring the most important insights appear immediately.
- Clear Interpretation
Confident Negative Results
Negative findings are clearly interpreted, helping clinicians confidently rule out actionable biomarkers and avoid unnecessary uncertainty.
- Safer Treatment
Drug Safety Alerts
Pharmacogenomic markers identify potential toxicity risks and dosing considerations before treatment begins.
- Trial Ready
Clinical Trial Matching
- Validated Evidence
Evidence-Based Insights
Every recommendation references trusted clinical guidelines and published evidence to support confident decision-making.
- AI Assisted
AI-Powered Clinical Summary
AI organizes DNA, RNA, biomarker, and clinical evidence into one concise treatment- ready summary.
Designed for Faster Clinical Decisions
Structured reports help oncologists move from genomic findings to treatment recommendations in minutes—not hours.
- Continuously validated
6
Evidence Layers
Multi-omic evidence integrated into every report.
3
Expert Review Levels
Reviewed through AI, molecular scientists, and clinical specialists.
Actionable Reporting
Every report is structured to support real clinical decision-making.
≤12 Days
Typical Turnaround
Fast reporting for timely treatment planning.
From sample to clinical decision in 7–12 days.
STEP 01
Patient
STEP 02
Sample Collection
STEP 03
Laboratory Analysis
STEP 04
AI Interpretation
STEP 05
Clinical Report
STEP 06
Treatment Decision
1,000+
Genes Covered
50,000+
Cases Reported
120+
Clinical Institutions
98%
Clinician Satisfaction
Bring precision oncology into every clinical decision.
Connect with our clinical team to design the right testing pathway for your patients, institution or research program.